# Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

> **NCT00572455** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 318 (actual)

## Conditions studied

- Primary Open-Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** PF-04217329 - Lowest Dose
- **DRUG:** PF-04217329 - Low Dose
- **DRUG:** PF-04217329 - Middle Dose
- **DRUG:** PF-04217329 - High Middle Dose
- **DRUG:** PF-04217329 - High Dose
- **DRUG:** PF-4217329 - Highest Dose
- **DRUG:** PF-04217329 - Vehicle
- **DRUG:** Latanoprost Vehicle
- **DRUG:** PF-04217329 - Low Dose
- **DRUG:** Latanoprost Vehicle
- **DRUG:** PF-04217329 - Middle Dose
- **DRUG:** Latanoprost Vehicle
- **DRUG:** PF-04217329 - High Dose
- **DRUG:** Latanoprost 0.005%
- **DRUG:** PF-04217329 - Low Dose
- **DRUG:** Latanoprost 0.005%
- **DRUG:** PF-04217329 - Middle Dose
- **DRUG:** Latanoprost 0.005%
- **DRUG:** PF-04217329 - High Dose
- **DRUG:** Latanoprost 0.005%

## Key facts

- **NCT ID:** NCT00572455
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-11
- **Primary completion:** 2009-06-26
- **Final completion:** 2009-06-26
- **Target enrollment:** 318 (ACTUAL)
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00572455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00572455, "Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00572455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*